Island Pharmaceuticals Ltd (ASX:ILA) CEO Dr David Foster tells Proactive the company has been granted human research ethics approval to commence its ISLA-101 Single Ascending Dose study. The aim of the study is to ensure that administered doses can safely achieve blood concentrations of ISLA-101 that are predicted to be effective against the dengue virus. Recruitment and dosing will commence imminently, with the data read out expected in early 2024.
Island Pharma welcomes green light for ISLA-101 clinical study
